Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.82 |
| ▸ | HIF1A | Q16665 | 10/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | NR3C1 | P04150 | 7/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.61 |
| ▸ | CNR1 | P21554 | 2/20 | 0.61 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.61 |
| ▸ | PGR | P06401 | 5/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.51 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6323667 | 1.00 | LMNA (0.82) | LMNASMN1; SMN2HIF1ACYP3A4ALDH1A1 | |
| SCHEMBL11525651 | 1.00 | LMNA (0.82) | LMNASMN1; SMN2HIF1ACYP3A4ALDH1A1 | |
| SCHEMBL11054021 | 0.90 | LMNA (1.00) | LMNASMN1; SMN2HIF1ACYP3A4ALDH1A1 | |
| SCHEMBL11054037 | 0.90 | LMNA (1.00) | LMNASMN1; SMN2HIF1ACYP3A4ALDH1A1 | |
| SCHEMBL11054008 | 0.90 | LMNA (1.00) | LMNASMN1; SMN2HIF1ACYP3A4ALDH1A1 | |
| SCHEMBL11649313 | 0.88 | LMNA (0.83) | LMNASMN1; SMN2HIF1ACYP3A4ALDH1A1 | |
| SCHEMBL11649307 | 0.88 | LMNA (0.83) | LMNASMN1; SMN2HIF1ACYP3A4ALDH1A1 | |
| SCHEMBL11649309 | 0.88 | LMNA (0.83) | LMNASMN1; SMN2HIF1ACYP3A4ALDH1A1 | |
| SCHEMBL11407501 | 0.88 | LMNA (0.64) | LMNASMN1; SMN2HIF1ACYP3A4ALDH1A1 | |
| SCHEMBL11407499 | 0.88 | LMNA (0.64) | LMNASMN1; SMN2HIF1ACYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050070515-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-31 | — | — | US | disclosed |
| EP-0998484-B1 | METHOD OF IDENTIFYING COMPOUNDS HAVING REDUCED SYSTEMIC EFFECTS | GLAXO GROUP LTD (GB) | 2004-03-03 | — | — | EP | disclosed |
| US-20020019378-A1 | COMPOUNDS | GLAXO WELLCOME INC. | 2002-02-14 | — | — | US | disclosed |
| EP-0998484-A1 | THARAPEUTICALLY ACTIVE COMPOUNDS WITH LOW SYSTEMIC ACTIVITY DUE TO REDUCED HALF-LIFE | GLAXO GROUP LIMITED (GB) | 2000-05-10 | — | — | EP | disclosed |
| WO-1999001467-A2 | THERAPEUTICALLY ACTIVE COMPOUNDS WITH LOW SYSTEMIC ACTIVITY DUE TO REDUCE HALF LIFE | GLAXO GROUP LIMITED (GB) | 1999-01-14 | — | — | WO | disclosed |
| US-4990612-A | 16α-methylation process | THE UPJOHN COMPANY (US) | 1991-02-05 | — | — | US | disclosed |
| EP-0165037-B1 | 16 ALPHA-METHYL STEROIDS AND THEIR PREPARATION | THE UPJOHN COMPANY (US) | 1990-09-19 | — | — | EP | disclosed |
| US-4929395-A | 16α-methylation process | THE UPJOHN COMPANY (US) | 1990-05-29 | — | — | US | disclosed |
| US-4891426-A | EPOXIDATION WITH PERACID | THE UPJOHN COMPANY (US) | 1990-01-02 | — | — | US | disclosed |
| US-4704455-A | 16α-methylatedΔ17(20)-corticoids | THE UPJOHN COMPANY (US) | 1987-11-03 | — | — | US | disclosed |
| EP-0165037-A2 | 16 alpha-methyl steroids and their preparation | THE UPJOHN COMPANY (US) | 1985-12-18 | — | — | EP | disclosed |
| US-4232013-A | ANTIINFLAMMATORY AGENTS, RHEUMATISM | LARK S.P.A. (IT) | 1980-11-04 | — | — | US | disclosed |
| US-4155917-A | WITH OZONE AND AN ALKANOL | E. R. SQUIBB & SONS, INC. (US) | 1979-05-22 | — | — | US | disclosed |
| EP-0000546-A1 | D-homo oxasteroids, processes for their preparation, their use in preparing pharmaceutical compositions with antiinflammatocy activity and pharmaceutical compositions containing them | E.R. Squibb & Sons, Inc. (US) | 1979-02-07 | — | — | EP | disclosed |
| US-4116978-A | ANTIINFLAMMATORY | E. R. SQUIBB & SONS, INC. (US) | 1978-09-26 | — | — | US | disclosed |
| US-4113722-A | Steroidal[16α,17-b]benzodioxins | E. R. SQUIBB & SONS, INC. (US) | 1978-09-12 | — | — | US | disclosed |
| US-4018774-A | ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1977-04-19 | — | — | US | disclosed |
| US-4018757-A | ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1977-04-19 | — | — | US | disclosed |
| US-3937720-A | ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1976-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019378-A1 | COMPOUNDS | ATP6V1E1, PSME1, ATP6V1H | LMNA 3880/4885SMN1; SMN2 3225/4885HIF1A 1534/4885 |
| US-20050070515-A1 | Compounds | LCT, LPO, LIPE | LMNA 3427/4885SMN1; SMN2 2435/4885HIF1A 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.